Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Motorola Solutions Announces Pricing Terms of its Tender Offers

Published

on

Reading Time: 6 minutes

CHICAGO–(BUSINESS WIRE)–Motorola Solutions, Inc. (NYSE: MSI) (the “Company”) announced
today the pricing terms of its previously announced tender offers to
purchase for cash (i) any and all of the Company’s outstanding
securities listed in Table I below (the “Any and All Notes”) (such
offer, the “Any and All Offer”), and (ii) up to the Maximum Waterfall
Tender Amount (as defined below) in aggregate purchase price of the
Company’s outstanding securities listed in Table II below (collectively,
the “Waterfall Notes” and, together with the Any and All Notes, the
“Securities”), subject to the Acceptance Priority Levels as defined
below (such offer, the “Waterfall Offer”). The “Maximum Waterfall Tender
Amount” is an aggregate purchase price equal to $650 million less
the aggregate purchase price of the Any and All Notes validly tendered
and accepted for purchase in the Any and All Offer. The Company also
announced the principal amount of each series of Securities that it
expects to accept pursuant to the tender offers, subject to the
satisfaction of waiver of certain conditions, as described below. The
tender offers are being made upon and are subject to the terms and
conditions set forth in the Offer to Purchase, dated May 9, 2019, as
amended earlier today, and the related Letter of Transmittal (as they
may each be further amended or supplemented from time to time, the
“Tender Offer Documents”).

The “Total Consideration” for each series of Securities is payable to
holders of the Securities who validly tendered and did not properly
withdraw their Securities at or prior to 5:00 p.m., New York City time,
on May 22, 2019 (the “Early Tender Deadline”) and whose Securities are
accepted for purchase by the Company. The Reference Yields listed in the
tables below were determined at 11:00 a.m., New York City time, on May
23, 2019 (the “Price Determination Date”) by the lead dealer managers.
Payments for Securities purchased in connection with the Early Tender
Deadline will also include accrued and unpaid interest from and
including the last interest payment date applicable to the relevant
series of Securities up to, but not including, the early settlement date
for such Securities accepted for purchase, which is currently expected
to be May 24, 2019 (the “Early Settlement Date”).

Table I

Securities Subject to the Any and All
Offer

 
Title of Security   Principal
Amount
Outstanding
  CUSIP/ISIN  

Principal Amount

Expected to be

Accepted(1)

  Reference U.S. Treasury
Security
  Reference Yield   Fixed Spread
(basis points)
 

 

Total

Consideration(2)

7.500% Senior Notes due 2025 $346,930,000 CUSIP: 620076 AH2
ISIN:US620076AH21
$90,076,000 2.250% U.S.T. due 04/30/24 2.126% 165 $1,197.52
6.500% Senior Notes due 2025 $117,892,000 CUSIP: 620076 AK5

ISIN: US620076AK59

$45,016,000 2.250% U.S.T. due 04/30/24 2.126% 170 $1,147.73
6.500% Senior Notes due 2028 $36,463,000 CUSIP: 620076 AP4

ISIN: US620076AP47

$11,501,000 2.625% U.S.T. due 02/15/29 2.336% 195 $1,170.91
6.625% Senior Notes due 2037 $54,533,000 CUSIP: 620076 BA6

ISIN: US620076BA68

$16,276,000 3.000% U.S.T. due 02/15/49 2.766% 285 $1,115.07
(1)   Expected to be accepted for purchase, and paid for, on the Early
Settlement Date.
(2) The total consideration payable for each $1,000 principal amount of
Securities validly tendered at or prior to the Expiration Date and
accepted for purchase by us includes an early tender premium of $50.
In addition, holders whose Securities are accepted will also receive
accrued interest on such Securities.

Table II

Securities Subject to the Waterfall Offer

 
Title of Security  

Principal Amount
Outstanding

  CUSIP/ISIN  

Acceptance

Priority
Level

 

Principal

Amount

Expected to be

Accepted(1)

 

Reference U.S.

Treasury
Security

 

Reference

Yield

 

Fixed Spread
(basis points)

 

 

Total Consideration(2)

3.500% Senior Notes due 2021 $400,000,000 CUSIP: 620076 BD0

ISIN: US620076BD08

1 $249,683,000 2.250% U.S.T. due 04/30/21 2.167% 50 $1,018.20
3.750% Senior Notes due 2022 $750,000,000 CUSIP: 620076 BB4

ISIN: US620076BB42

2 $198,233,000 2.250% U.S.T. due 04/15/22 2.115% 50 $1,032.28
3.500% Senior Notes due 2023 $600,000,000 CUSIP: 620076 BC2

ISIN: US620076BC25

3 $0 2.250% U.S.T. due 04/30/24 N/A 80 N/A
(1)   Expected to be accepted for purchase, and paid for, on the Early
Settlement Date.
(2) The total consideration payable for each $1,000 principal amount of
Securities validly tendered at or prior to the Early Tender Deadline
and accepted for purchase by us includes an early tender premium of
$50. In addition, holders whose Securities are accepted will also
receive accrued interest on such Securities.

As listed in the tables above, the Company expects to accept for
purchase, and pay for, $90,076,000 aggregate principal amount of its
7.500% Senior Notes due 2025, $45,016,000 aggregate principal amount of
its 6.500% Senior Notes due 2025, $11,501,000 aggregate principal amount
of its 6.500% Senior Notes due 2028, $16,276,000 aggregate principal
amount of its 6.625% Senior Notes due 2037, $249,683,000 aggregate
principal amount of its 3.500% Senior Notes due 2021 and $198,233,000
aggregate principal amount of its 3.750% Senior Notes due 2022, on the
Early Settlement Date.

The Company’s obligation to accept for payment and pay for the
Securities validly tendered in the tender offers is subject to the
satisfaction or waiver of the conditions described in the Offer to
Purchase.

Although the tender offers are scheduled to expire at midnight, New York
City time, at the end of June 6, 2019, unless extended or terminated,
because the Waterfall Offer was fully subscribed as of the Early Tender
Deadline, the Company does not expect to accept for purchase any
Waterfall Notes tendered after the Early Tender Deadline. Holders of Any
and All Notes who validly tender such notes following the Early Tender
Deadline and at or prior to the Expiration Date will receive the
applicable Total Consideration for Securities accepted for purchase
specified in the table above. Securities not accepted for purchase will
be promptly returned or credited to the holder’s account. The withdrawal
deadline of 5:00 p.m., New York City time, on May 22, 2019 has passed
and, accordingly, Securities validly tendered in the tender offers may
no longer be withdrawn except where additional withdrawal rights are
required by law.

BofA Merrill Lynch and Mizuho Securities are serving as the Lead Dealer
Managers, and Santander, TD Securities and US Bancorp are serving as the
Co-Dealer Managers, in connection with the tender offers. The
information agent and tender agent is Global Bondholder Services
Corporation. The full details of the tender offers, including complete
instructions on how to tender Securities, are included in the Tender
Offer Documents. Holders are strongly encouraged to read carefully the
Tender Offer Documents, including materials incorporated by reference
therein, because they contain important information. Copies of the
Tender Offer Documents and related offering materials are available by
contacting the information agent at (212) 430-3774 (banks and brokers)
or (866) 807-2200 (all others). Questions regarding the tender offers
should be directed to BofA Merrill Lynch, at (980) 387-3907 or (888)
292-0070 (toll free) or Mizuho Securities, at (212) 205-7736 or (866)
271-7403 (toll free).

None of the Company or its affiliates, their respective boards of
directors, the dealer managers, the information agent and tender agent
or the trustee is making any recommendation as to whether holders should
tender any Securities in response to any of the tender offers, and
neither the Company nor any such other person has authorized any person
to make any such recommendation. Holders must make their own decision as
to whether to tender any of their Securities, and, if so, the principal
amount of Securities to tender.

This news release shall not constitute an offer to sell, a solicitation
to buy or an offer to purchase or sell any securities. The tender offers
are being made only pursuant to the Offer to Purchase and only in such
jurisdictions as is permitted under applicable law.

About Motorola Solutions, Inc.

Motorola Solutions is a global leader in mission-critical
communications. Our technology platforms in communications, command
center software, services and video security and analytics make cities
safer and help communities and businesses thrive. At Motorola Solutions,
we are ushering in a new era in public safety and security. Learn more
at www.motorolasolutions.com.

Cautionary Note Regarding Forward-Looking
Statements

This press release contains statements that constitute “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995 and other federal securities laws. These
“forward-looking statements” are statements other than statements of
historical fact and may include, among other things, statements in
relation to the Company’s current expectations and beliefs as to its
ability to consummate the tender offers, including the timing, size,
pricing or other terms of the tender offers, and other future events.
All information set forth in this release is as of the date hereof. The
Company does not intend, and undertakes no duty, to update this
information to reflect future events or circumstances. Actual results
are subject to a number of risks and uncertainties and may differ
materially from the current expectations and beliefs discussed in this
press release. Certain potential factors, risks and uncertainties that
could affect the Company’s business and financial results and cause
actual results to differ materially from those expressed or implied in
any forward-looking statements include the Company’s ability to complete
the tender offers and satisfy the conditions thereto, and other
potential factors, risks and uncertainties under the heading “Risk
Factors” in its Annual Report on Form 10-K for the year ended December
31, 2018, which is on file with the Securities and Exchange Commission
(“SEC”) and available at the SEC’s website at www.sec.gov.

MOTOROLA, MOTOROLA SOLUTIONS and the Stylized M Logo are trademarks
or registered trademarks of Motorola Trademark Holdings, LLC and are
used under license. All other trademarks are the property of their
respective owners. ©2019 Motorola Solutions, Inc. All rights reserved.

Contacts

Investor Contact:
Uygar Gazioglu
Motorola Solutions
+1
847-250-6149
[email protected]

Media Contact:
Kate Dyer
Motorola Solutions
+1
224-374-3124
[email protected]


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect

Published

on

Continue Reading

Cannabis

Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand

Published

on

Continue Reading

transfer

IMC to transfer its Oranim Pharmacy shares back to the seller

Published

on

imc-to-transfer-its-oranim-pharmacy-shares-back-to-the-seller

TORONTO and GLIL YAM, Israel, April 16, 2024 /PRNewswire/ — IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC) (the “Company” or “IMC“), a leading medical cannabis company with operations in Israel and Germany, is announcing that, further to the news release dated January 12, 2024, the Company has decided not to make remaining installment payments installments (i.e. NIS 5,873K including interest or 2,154K CAD) by IMC Holdings Ltd., and as such will transfer the 51% shares held by IMC Holdings Ltd back to the  seller.

“With the April 1st cannabis legalization in Germany, we are focusing our resources on the German market, where we expect to see the biggest growth potential,” said Oren Shuster, CEO of IMC. “With both of our core markets, Germany and Israel, currently undergoing rapid evolution, we need to assure that we allocate our resources to the growth opportunities where we expect the best return on investment.”

About IM Cannabis Corp.

IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has recently exited operations in Canada to pivot its focus and resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC’s products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. Until recently, the Company also actively operated in Canada through Trichome Financial Corp and its wholly owned subsidiaries, where it cultivated, processed, packaged, and sold premium and ultra-premium cannabis at its own facilities under the WAGNERS and Highland Grow brands for the adult-use market in Canada. The Company has exited operations in Canada and considers these operations discontinued.

Disclaimer for Forward-Looking Statements

This press release contains forward-looking information or forward-looking statements under applicable Canadian and U.S. securities laws (collectively, “forward-looking statements”). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to,  the occurrence of growth opportunities and the likelihood of growth potential.

Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the development and introduction of new products; continuing demand for medical and adult-use recreational cannabis in the markets in which the Company operates; the Company’s ability to reach patients through both e-commerce and brick and mortar retail operations; the Company’s ability to maintain and renew or obtain required licenses; the effectiveness of its products for medical cannabis patients and recreational consumers; and the Company’s ability to market its brands and services successfully to its anticipated customers and medical cannabis patients.

The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward looking statements due to a number of factors and risks. These include: any failure of the Company to maintain “de facto” control over Focus Medical in accordance with IFRS 10; the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the effect of the reform on the Company; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and Focus Medical (collectively, the “Group”) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt and war, conflict and civil unrest in Eastern Europe and the Middle East

Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made.

The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

Company Contacts:

Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]

Oren Shuster, Chief Executive Officer
IM Cannabis Corp.
[email protected]

Logo – https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/imc-to-transfer-its-oranim-pharmacy-shares-back-to-the-seller-302117984.html

Continue Reading

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania